Copyright Reports & Markets. All rights reserved.

Global Erlotinib Generics Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Erlotinib Generics Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 25mg per Tablet
    • 1.3.3 100mg per Tablet
    • 1.3.4 150mg per Tablet
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Erlotinib Generics Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital and Clinic
    • 1.4.3 Retail Pharmacies
    • 1.4.4 Other
  • 1.5 Global Erlotinib Generics Market Size & Forecast
    • 1.5.1 Global Erlotinib Generics Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Erlotinib Generics Sales Quantity (2021-2032)
    • 1.5.3 Global Erlotinib Generics Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Teva
    • 2.1.1 Teva Details
    • 2.1.2 Teva Major Business
    • 2.1.3 Teva Erlotinib Generics Product and Services
    • 2.1.4 Teva Erlotinib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Teva Recent Developments/Updates
  • 2.2 Mylan
    • 2.2.1 Mylan Details
    • 2.2.2 Mylan Major Business
    • 2.2.3 Mylan Erlotinib Generics Product and Services
    • 2.2.4 Mylan Erlotinib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Mylan Recent Developments/Updates
  • 2.3 Glenmark Pharmaceuticals
    • 2.3.1 Glenmark Pharmaceuticals Details
    • 2.3.2 Glenmark Pharmaceuticals Major Business
    • 2.3.3 Glenmark Pharmaceuticals Erlotinib Generics Product and Services
    • 2.3.4 Glenmark Pharmaceuticals Erlotinib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Glenmark Pharmaceuticals Recent Developments/Updates
  • 2.4 Cipla
    • 2.4.1 Cipla Details
    • 2.4.2 Cipla Major Business
    • 2.4.3 Cipla Erlotinib Generics Product and Services
    • 2.4.4 Cipla Erlotinib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Cipla Recent Developments/Updates
  • 2.5 Natco Pharma
    • 2.5.1 Natco Pharma Details
    • 2.5.2 Natco Pharma Major Business
    • 2.5.3 Natco Pharma Erlotinib Generics Product and Services
    • 2.5.4 Natco Pharma Erlotinib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Natco Pharma Recent Developments/Updates
  • 2.6 Aristopharma
    • 2.6.1 Aristopharma Details
    • 2.6.2 Aristopharma Major Business
    • 2.6.3 Aristopharma Erlotinib Generics Product and Services
    • 2.6.4 Aristopharma Erlotinib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Aristopharma Recent Developments/Updates
  • 2.7 Taj Pharma
    • 2.7.1 Taj Pharma Details
    • 2.7.2 Taj Pharma Major Business
    • 2.7.3 Taj Pharma Erlotinib Generics Product and Services
    • 2.7.4 Taj Pharma Erlotinib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Taj Pharma Recent Developments/Updates
  • 2.8 Sun Pharmaceutical
    • 2.8.1 Sun Pharmaceutical Details
    • 2.8.2 Sun Pharmaceutical Major Business
    • 2.8.3 Sun Pharmaceutical Erlotinib Generics Product and Services
    • 2.8.4 Sun Pharmaceutical Erlotinib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Sun Pharmaceutical Recent Developments/Updates
  • 2.9 Jilin Aodong Taonan Pharmaceutical
    • 2.9.1 Jilin Aodong Taonan Pharmaceutical Details
    • 2.9.2 Jilin Aodong Taonan Pharmaceutical Major Business
    • 2.9.3 Jilin Aodong Taonan Pharmaceutical Erlotinib Generics Product and Services
    • 2.9.4 Jilin Aodong Taonan Pharmaceutical Erlotinib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Jilin Aodong Taonan Pharmaceutical Recent Developments/Updates
  • 2.10 Acebright Pharma
    • 2.10.1 Acebright Pharma Details
    • 2.10.2 Acebright Pharma Major Business
    • 2.10.3 Acebright Pharma Erlotinib Generics Product and Services
    • 2.10.4 Acebright Pharma Erlotinib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Acebright Pharma Recent Developments/Updates
  • 2.11 Shandong Loncom Pharma
    • 2.11.1 Shandong Loncom Pharma Details
    • 2.11.2 Shandong Loncom Pharma Major Business
    • 2.11.3 Shandong Loncom Pharma Erlotinib Generics Product and Services
    • 2.11.4 Shandong Loncom Pharma Erlotinib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Shandong Loncom Pharma Recent Developments/Updates
  • 2.12 Hansoh Pharma
    • 2.12.1 Hansoh Pharma Details
    • 2.12.2 Hansoh Pharma Major Business
    • 2.12.3 Hansoh Pharma Erlotinib Generics Product and Services
    • 2.12.4 Hansoh Pharma Erlotinib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Hansoh Pharma Recent Developments/Updates
  • 2.13 Thery Pharm
    • 2.13.1 Thery Pharm Details
    • 2.13.2 Thery Pharm Major Business
    • 2.13.3 Thery Pharm Erlotinib Generics Product and Services
    • 2.13.4 Thery Pharm Erlotinib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Thery Pharm Recent Developments/Updates
  • 2.14 Shenzhen Salubris Pharmaceuticals
    • 2.14.1 Shenzhen Salubris Pharmaceuticals Details
    • 2.14.2 Shenzhen Salubris Pharmaceuticals Major Business
    • 2.14.3 Shenzhen Salubris Pharmaceuticals Erlotinib Generics Product and Services
    • 2.14.4 Shenzhen Salubris Pharmaceuticals Erlotinib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Shenzhen Salubris Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: Erlotinib Generics by Manufacturer

  • 3.1 Global Erlotinib Generics Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Erlotinib Generics Revenue by Manufacturer (2021-2026)
  • 3.3 Global Erlotinib Generics Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Erlotinib Generics by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Erlotinib Generics Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Erlotinib Generics Manufacturer Market Share in 2025
  • 3.5 Erlotinib Generics Market: Overall Company Footprint Analysis
    • 3.5.1 Erlotinib Generics Market: Region Footprint
    • 3.5.2 Erlotinib Generics Market: Company Product Type Footprint
    • 3.5.3 Erlotinib Generics Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Erlotinib Generics Market Size by Region
    • 4.1.1 Global Erlotinib Generics Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Erlotinib Generics Consumption Value by Region (2021-2032)
    • 4.1.3 Global Erlotinib Generics Average Price by Region (2021-2032)
  • 4.2 North America Erlotinib Generics Consumption Value (2021-2032)
  • 4.3 Europe Erlotinib Generics Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Erlotinib Generics Consumption Value (2021-2032)
  • 4.5 South America Erlotinib Generics Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Erlotinib Generics Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Erlotinib Generics Sales Quantity by Type (2021-2032)
  • 5.2 Global Erlotinib Generics Consumption Value by Type (2021-2032)
  • 5.3 Global Erlotinib Generics Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Erlotinib Generics Sales Quantity by Application (2021-2032)
  • 6.2 Global Erlotinib Generics Consumption Value by Application (2021-2032)
  • 6.3 Global Erlotinib Generics Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Erlotinib Generics Sales Quantity by Type (2021-2032)
  • 7.2 North America Erlotinib Generics Sales Quantity by Application (2021-2032)
  • 7.3 North America Erlotinib Generics Market Size by Country
    • 7.3.1 North America Erlotinib Generics Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Erlotinib Generics Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Erlotinib Generics Sales Quantity by Type (2021-2032)
  • 8.2 Europe Erlotinib Generics Sales Quantity by Application (2021-2032)
  • 8.3 Europe Erlotinib Generics Market Size by Country
    • 8.3.1 Europe Erlotinib Generics Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Erlotinib Generics Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Erlotinib Generics Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Erlotinib Generics Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Erlotinib Generics Market Size by Region
    • 9.3.1 Asia-Pacific Erlotinib Generics Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Erlotinib Generics Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Erlotinib Generics Sales Quantity by Type (2021-2032)
  • 10.2 South America Erlotinib Generics Sales Quantity by Application (2021-2032)
  • 10.3 South America Erlotinib Generics Market Size by Country
    • 10.3.1 South America Erlotinib Generics Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Erlotinib Generics Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Erlotinib Generics Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Erlotinib Generics Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Erlotinib Generics Market Size by Country
    • 11.3.1 Middle East & Africa Erlotinib Generics Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Erlotinib Generics Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Erlotinib Generics Market Drivers
  • 12.2 Erlotinib Generics Market Restraints
  • 12.3 Erlotinib Generics Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Erlotinib Generics and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Erlotinib Generics
  • 13.3 Erlotinib Generics Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Erlotinib Generics Typical Distributors
  • 14.3 Erlotinib Generics Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Erlotinib Generics market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Erlotinib generics are pharmaceutical formulations of the drug erlotinib that are produced and marketed under different brand names by various manufacturers after the original patent on the brand-name drug has expired.These generic versions contain the same active ingredient and are designed to work in the same way as the brand-name drug, targeting the epidermal growth factor receptor (EGFR) to inhibit the growth of cancer cells.
    This report is a detailed and comprehensive analysis for global Erlotinib Generics market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Erlotinib Generics market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Erlotinib Generics market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Erlotinib Generics market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Erlotinib Generics market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Erlotinib Generics
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Erlotinib Generics market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Teva, Mylan, Glenmark Pharmaceuticals, Cipla, Natco Pharma, Aristopharma, Taj Pharma, Sun Pharmaceutical, Jilin Aodong Taonan Pharmaceutical, Acebright Pharma, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Erlotinib Generics market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    25mg per Tablet
    100mg per Tablet
    150mg per Tablet
    Market segment by Application
    Hospital and Clinic
    Retail Pharmacies
    Other
    Major players covered
    Teva
    Mylan
    Glenmark Pharmaceuticals
    Cipla
    Natco Pharma
    Aristopharma
    Taj Pharma
    Sun Pharmaceutical
    Jilin Aodong Taonan Pharmaceutical
    Acebright Pharma
    Shandong Loncom Pharma
    Hansoh Pharma
    Thery Pharm
    Shenzhen Salubris Pharmaceuticals
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Erlotinib Generics product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Erlotinib Generics, with price, sales quantity, revenue, and global market share of Erlotinib Generics from 2021 to 2026.
    Chapter 3, the Erlotinib Generics competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Erlotinib Generics breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Erlotinib Generics market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Erlotinib Generics.
    Chapter 14 and 15, to describe Erlotinib Generics sales channel, distributors, customers, research findings and conclusion.

    Buy now